Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow
Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...
Regeneron Pharmaceuticals (NasdaqGS:REGN) Drops 10% Over Last Week Despite Dupixent Approval in Japan
Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the ...
Medical Marketing & Media1d
Boosted by March Madness, Tremfya takes the lead in TV pharma ad rankings
Tremfya achieved an impressions share of voice (SOV) of 3.35%, generating 2.1 billion total impressions. While the brand held ...
Healio1d
Dupilumab, tezepelumab lead biologic initiations for severe asthma
Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...
Is Regeneron Pharmaceuticals, Inc. (REGN) The Most Profitable Biotech Stock To Buy Right Now?
We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...
Healio4d
Patients with severe asthma need fewer steroid bursts with tezepelumab-ekko
Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization ...
Regeneron price target lowered to $1,000 from $1,100 at JPMorgan
JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,100 and keeps an Overweight rating on the shares. The firm ...
Regeneron Pharmaceuticals, Inc. (REGN): Among Blue Chip Stocks to Invest in at 52-Week Lows
We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...